Abstracts Archive - Page 1681 of 2425 - ACR Meeting Abstracts

Abstract Number: 3136 • 2015 ACR/ARHP Annual Meeting
Impact of Prokinetic Agents on Systemic Sclerosis-Associated Gastrointestinal Disease: A Systematic Review
Annaliese Tisseverasinghe¹, Ahmad Kadhim², Ambica Parmar², Louis Liu² and Sindhu R. Johnson¹, ¹Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, Mount Sinai Hospital, Institue of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ²Division of Gastroenterology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: More than 90% of patients with Systemic Sclerosis (SSc) have gastroinstestinal (GI) involvement, commonly dysmotility causing complications such as gastroesophageal reflux and constipation. Treatment…
Abstract Number: 3137 • 2015 ACR/ARHP Annual Meeting
Scleroderma Hand Contracture Study
Joyce Joseph, Rheumatology, Univeristy of Teas Health Science Center at Houston, Houston, TX
Background/Purpose: To investigate the progression of hand contractures in patients with systemic sclerosis and to identify disease features predictive of contractures. A sub-group analysis was…
Abstract Number: 3138 • 2015 ACR/ARHP Annual Meeting
Prognostic Role of Ventricular Ectopic Beats in Systemic Sclerosis
Giacomo De Luca¹, Silvia Laura Bosello¹, Francesca Gabrielli², Giorgia Berardi¹, Federico parisi¹, Manuela Rucco¹, Giovanni Canestrari¹, Leonarda Galiuto³, Filippo Crea³, Francesco Loperfido² and Gianfranco Ferraccioli¹, ¹Division of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, ²Division of Heart Failure and Cardiac Rehabilitation, Catholic University - Rome, Rome, Italy, ³Institute of Cardiology, Catholic University of the Sacred Heart, Rome, Italy
Background/Purpose: Heart involvement is common during Systemic Sclerosis (SSc), even if often clinically silent, and represents the leading cause of death in about one third…
Abstract Number: 3139 • 2015 ACR/ARHP Annual Meeting
Screening Algorithm for Pulmonary Hypertension in Systemic Sclerosis – Comparison of Predictive Accuracy of Three Algorithms
Vivek Nagaraja¹, Scott H. Visovatti², Heather Gladue³, Veronica J. Berrocal⁴, Jennifer Serrano⁵, Vallerie McLaughlin² and Dinesh Khanna⁶, ¹Department of Medicine [Division of Rheumatology], University of Toledo, Toledo, OH, ²Internal Medicine, Division of Cardiology, University of Michigan, Ann Arbor, MI, ³Rheumatology, Emory University, Atlanta, GA, ⁴Div of Rheumatology, University of Michigan, Ann Arbor, MI, ⁵University of Michigan, Ann Arbor, MI, ⁶Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Pulmonary arterial hypertension (PAH) is the leading cause of mortality in systemic sclerosis (SSc), and is associated with a 3-year survival of approximately 50%.…
Abstract Number: 3140 • 2015 ACR/ARHP Annual Meeting
A Meta-Immunochip Analysis Suggests IL12B As a Common Susceptibility Factor for Large-Vessel Vasculitides
Francisco David Carmona¹, Patrick Coit², Güher Saruhan-Direskeneli³, Maria C. Cid⁴, Roser Solans⁵, Santos Castañeda⁶, Augusto Vaglio (on behalf of the Italian GCA Study Group)⁷, Haner Direskeneli (on behalf of the Turkish Takayasu Study Group)⁸, Peter A. Merkel⁹, Carlo Salvarani¹⁰, Miguel A. Gonzalez-Gay¹¹, Javier Martín¹², Amr H. Sawalha² and Spanish GCA consortium, ¹Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, PTS-Granada, Granada, Spain, ²Division of Rheumatology, University of Michigan, Ann Arbor, MI, ³Department of Physiology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ⁴Autoimmune and Systemic Diseases, Hospital Clínic. IDIBAPS. University of Barcelona, Barcelona, Spain, ⁵Department of Internal Medicine, Hospital Vall d'Hebron, Barcelona, Spain, ⁶Rheumatology, H.U. La Princesa, Madrid, Spain, ⁷Medicina Clinica e Nefrologia, Università di Parma, Parma, Italy, ⁸Department of Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ⁹Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁰Azienda Ospedaliera ASMN, Istituto di Ricovero e Cura a Carattere Scientifico, Reggio Emilia, Italy, ¹¹Reumatologia, Hospital Universitario Marqués de Valdecilla, IDIVAL, University of Cantabria, Santander, Spain, ¹²Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla (Granada), Spain
Background/Purpose: Large-vessel vasculitides (LVV) comprise giant cell arteritis (GCA) and Takayasu arteritis (TAK). They are characterized by self-sustaining inflammatory damage of the wall of large-sized…
Abstract Number: 3141 • 2015 ACR/ARHP Annual Meeting
Endothelial Cells Regulate Proinflammatory T Cell Responses in Large Vessel Vasculitis Via NOTCH-NOTCH Ligand Interactions
Zhenke Wen¹, Hui Zhang¹, Joyce Liao², Gerald Berry³, Lindsy J. Forbess⁴, Michael Weissman⁵, Jorg Goronzy¹ and Cornelia M. Weyand⁶, ¹Medicine: Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ²Byers Eye Institute at Stanford, Stanford University, Palo Alto, CA, ³Pathology, Stanford University School of Medicine, Stanford, CA, ⁴Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁵Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁶Medicine, Stanford University School of Medicine, Stanford, CA
Background/Purpose: In large vessel vasculitis (LVV), inflammatory infiltrates typically accumulate within the mural layers of the aorta and its major branches and are composed of…
Abstract Number: 3142 • 2015 ACR/ARHP Annual Meeting
Tocilizumab Enhances Regulatory T-Cell Activation and Proliferation in Giant Cell Arteritis
Chie Miyabe¹, Klemen Strle², Yoshishige Miyabe¹, John H. Stone^1,3, Andrew D. Luster^1,4 and Sebastian Unizony^1,5, ¹Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Allergy & Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Massachusetts General Hospital, Charlestown, MA, ⁵Rheumatology, Massachusetts General Hospital, Boston, MA
Background/Purpose : CD4+ T helper (Th) 17 cells, Th1 cells, and regulatory T-cells (Treg) contribute to the pathogenesis of giant cell arteritis (GCA). Interleukin (IL)-6,…
Abstract Number: 3143 • 2015 ACR/ARHP Annual Meeting
Mapping the Back-Door Routes into the Vascular Wall: 3D Microscopic Reconstruction of Microvasculature in the Normal Temporal Artery and in Giant Cell Arteritis
Daniel Drayton¹, Aruna Chakrabarty², Ann Morgan³, Darren Treanor⁴ and Sarah Mackie⁵, ¹School of Medicine, University of Leeds, Leeds, United Kingdom, ²Department of Cellular Pathology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine and NIHR-Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom, ⁴Leeds Institute of Cancer and Pathology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁵NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, University of Leeds, Leeds, United Kingdom
Background/Purpose: The arterial wall is nourished by microvessels (vasa vasorum), which are a potential route of entry for inflammatory cells in vasculitis. Little is known…
Abstract Number: 3144 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Tocilizumab for Polymyalgia Rheumatica
Lindsay Lally¹, Lindsy J. Forbess², Chris Hatzis¹ and Robert F. Spiera³, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ³Rheumatology, HSS, New York, NY
Background/Purpose: IL-6 is a pivotal cytokine in PMR pathogenesis, yet the efficacy of IL-6 blockade with tocilizumab (TCZ) for treatment of PMR is unknown. The…
Abstract Number: 3145 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Modified-Release Prednisone in Patients with Polymyalgia Rheumatica: Results of a Multicenter, Randomized, Active-Controlled Phase 3 Study
Maurizio Cutolo¹, Michael Hopp², Stefan Liebscher², Bhaskar Dasgupta³ and Frank Buttgereit⁴, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy, ²Medical Science, Mundipharma Research GmbH & Co. KG, Limburg, Germany, ³Rheumatology, Southend University Hospital, Essex, United Kingdom, ⁴Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Polymyalgia rheumatica (PMR) is characterized by persisting proximal pain and morning stiffness of the neck, shoulder and hip girdles of 2 weeks' duration, an…
Abstract Number: 3146 • 2015 ACR/ARHP Annual Meeting
Health Related Quality of Life in Adults with JIA – a 30 Year Longitudinal Study
Anita Tollisen^1,2,3, Anne Marit Selvaag¹, Hanne A. Aulie¹, Anners Lerdal^4,5 and Berit Flato^1,2, ¹Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, ²Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway, ³Department of Medicine, Lovisenberg Diakonale Hospital, Oslo, Oslo, Norway, ⁴Faculty of Medicine, Institute of Health and Society, University of Oslo, Oslo, Norway, ⁵Lovisenberg Diakonale Hospital, Oslo, Oslo, Norway
Background/Purpose: Improvement of health-related quality of life (HRQOL) is a central aim in treatment of patients with JIA. The primary aim of the study is…
Abstract Number: 3147 • 2015 ACR/ARHP Annual Meeting
Inter-Provider Reliability in Scoring the Physician Global Assessment of Disease Activity Among Patients with Juvenile Idiopathic Arthritis Patients Who Met the ACR Provisional Criteria for Clinical Inactive Disease
Janalee Taylor¹, Edward H. Giannini¹, Daniel Lovell² and Esi M. Morgan DeWitt¹, ¹Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Background/Purpose: With the advent and implementation of advanced drug therapy clinical inactive disease (CID) has become an attainable target in the treatment of juvenile idiopathic…
Abstract Number: 3148 • 2015 ACR/ARHP Annual Meeting
Physical Activity in Children and Adolescents with Juvenile Idiopathic Arthritis and Associated Factors
Sabrina Cavallo¹, Marie-Ève Mathieu², Annette Majnemer³, Désirée B. Maltais⁴, Ciarán M. Duffy⁵, Mélanie Henderson⁶ and Debbie Ehrmann Feldman⁷, ¹École de Santé Publique, Université de Montréal, Montreal, QC, Canada, ²Département de Kinésiologie, Université de Montréal, Montréal, QC, Canada, ³School of Physical and Occupational therapy, McGill University, Montreal, QC, Canada, ⁴Département de Réadaptation, Université de Laval, Québec, QC, Canada, ⁵Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ⁶Centre de recherche du Centre Hospitalier Universitaire Sainte-Justine, Montréal, QC, Canada, ⁷School of Rehabilitation, Université de Montréal, Montreal, QC, Canada
Background/Purpose: Physical activity has health benefits for all children and adolescents, including those with juvenile idiopathic arthritis (JIA). Our study aimed 1) to determine whether…
Abstract Number: 3149 • 2015 ACR/ARHP Annual Meeting
Predictors of Longitudinal Quality of Life Impact in Pediatric Localized Scleroderma
Kaveh Ardalan, Christina Kelsey and Kathryn S. Torok, Pediatric Rheumatology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA
Background/Purpose: Localized scleroderma (LS) is an autoimmune disease characterized by inflammation and fibrosis of the skin and a wide range of extracutaneous manifestations (ECMs). The…
Abstract Number: 3150 • 2015 ACR/ARHP Annual Meeting
Virtual Peer-to-Peer Mentoring Support for Adolescents with Juvenile Idiopathic Arthritis: The Virtual Peer-to-Peer Program
Jennifer N. Stinson¹, Sara Ahola Kohut^2,3, Khush Amaria², Mary J. Bell⁴, Paula Forgeron⁵, Miriam Kaufman⁶, Nadia Luca⁷ and Lynn R. Spiegel⁸, ¹Anesthesia and Pain Medicine, The Hospital for Sick Children, Toronto, ON, Canada, ²Hospital for Sick Children, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴Rheum Div/Univ of Toronto, University of Toronto, Toronto, ON, Canada, ⁵University of Ottawa, Ottawa, ON, Canada, ⁶Adolescent Medicine, The Hospital for Sick Children, Toronto, ON, Canada, ⁷Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁸Rheumatology/Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is a common chronic disease that results in physical and emotional symptoms as well as difficulties in social and role…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].